Candel Therapeutics, Inc.
CADL
$4.91
-$0.13-2.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -109.59% | -5.85% | 78.43% | 189.76% | -26.84% |
| Total Depreciation and Amortization | -33.47% | -20.41% | -2.81% | -2.39% | -1.61% |
| Total Amortization of Deferred Charges | 405.77% | -66.13% | -56.16% | -46.99% | -39.53% |
| Total Other Non-Cash Items | 106.50% | -84.22% | -129.04% | -1,378.43% | 314.65% |
| Change in Net Operating Assets | 383.85% | -57.82% | -84.81% | -8.50% | -53.48% |
| Cash from Operations | -81.77% | -55.73% | -43.45% | -2.11% | 21.67% |
| Capital Expenditure | -13,533.33% | -- | -416.67% | 57.14% | 93.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -13,533.33% | -- | -416.67% | 57.14% | 88.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -69.32% | 0.00% | 0.00% | -49.97% | -- |
| Issuance of Common Stock | -100.00% | -- | 348.68% | 52.91% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -52.24% | -301.01% | 796.86% | -49.00% | 76,061.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.77% | -180.31% | 300.09% | -8.13% | 1,237.33% |